Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
The world continues to battle against two pandemics: COVID-19 and tuberculosis (TB). Today, March 24, marks World TB Day and TB Alliance is joining...
TB Alliance, a not-for-profit organization dedicated to development and delivery of improved regimens to fight tuberculosis (TB), has added four new...
Le pretomanid, un nouveau composé développé par l'organisation à but non lucratif TB Alliance, a reçu une autorisation de mise sur le marché...
Der von der gemeinnützigen Organisation TB Alliance entwickelte neuartige Wirkstoff Pretomanid hat von der Europäischen Kommission eine bedingte...
El nuevo compuesto, Pretomanid desarrollado por la organización sin fines de lucro TB Alliance, ha recibido la autorización condicional de...
Pretomanid, een nieuw middel dat door de non-profitorganisatie TB Alliance is ontwikkeld, heeft van de Europese Commissie (EC) een voorwaardelijke...
Pretomanid, a novel compound developed by the non-profit organization TB Alliance, has been granted a conditional marketing authorisation by the...
TB Alliance has appointed Dr. Daniel Everitt to the position of Vice President and Chief Medical Officer. In this role, Dr. Everitt will lead TB...
TB Alliance, a not-for-profit organization dedicated to developing new drug regimens to fight tuberculosis (TB), has appointed Dr. Jane Griffiths to...
Pretomanid, a novel compound developed by the non-profit organization TB Alliance, was approved by the U.S. Food & Drug Administration (FDA) today...
TB Alliance today announced the appointment of Eugene Sun, MD to the position of Senior Vice President for Research and Development. Dr. Sun will...
TB Alliance, a not-for-profit organization leading the development of new, improved and affordable tuberculosis (TB) treatments, today announced that ...
TB Alliance announced today that the U.S. Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee voted (14 yes, 4 no, 0 abstain)...
TB Alliance, a not-for-profit organization dedicated to developing new drug regimens to fight tuberculosis (TB), has appointed Dr. Jan Lundberg to...
TB Alliance today announced the appointment of Angela Vanderploeg as Chief Financial Officer. Ms. Vanderploeg joins TB Alliance most recently from...
TB Alliance, a not-for-profit organization dedicated to finding faster-acting and affordable drug regimens to fight tuberculosis (TB), has appointed...
TB Alliance today announced the appointment of Dr. Ariel Pablos-Méndez to its board of directors. As a physician and a leader in global public...
TB Alliance and its partners announced today the availability of child-friendly tuberculosis (TB) medicines in the correct doses. The improved...
TB Alliance and its partners announced the start of a clinical trial of a new regimen to treat extensively drug-resistant tuberculosis (XDR-TB.) It...
TB Alliance und seine Partner kündigen den Start einer klinischen Studie eines neuen Therapieansatzes zur Behandlung von äußerst...
TB Alliance has announced a new partnership with the U.S. Fund for UNICEF that will dramatically increase the scope and impact of child and maternal...
TB Alliance, a not-for-profit product development partnership with the mission of developing better, faster, and affordable drugs for tuberculosis...
Een nieuwe medicijncombinatie tegen tuberculose (tbc), ontwikkeld om de mogelijkheden voor de behandeling van tbc te vergroten, doodt méér bacteriën...
TB Alliance has announced the start of the first human trial of a new tuberculosis (TB) drug candidate, designated TBA-354. It is the first new TB...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.